Investor Presentaiton

||| Viveo Background Background Viveo started its activities in 1996 as a distributor of hospital materials and medicines, founded by entrepreneur Carlos Ma- fra in Ribeirão Preto (SP). In an intense growth period, it ceased to be a limited company in 2015 and in the following year it became a shareholder in DNA Capital a healthcare-fo- cused investment fund. The inflow of capital into the business marked the beginning of a new expansion strategy, accelerat- ing the acquisition of assets and the formation of a business ecosystem. Among the first assets acquired were Tecnocold in 2017, spe- cialized in vaccine distribution. Cremer was integrated into the company the following year with 86 years of history, the industry leader specializes in the manufacture of items for first aid, surgery, treatment, and hygiene. Given the inorganic growth, in 2020, the process of acquiring Expresso, a medical distributor that had been operating for more than three de- cades in Brazil now represented by the commercial brand Mafra Hospitalar - was completed. In the same year, the business was driven by the acquisition of four more companies: Biogenetix, Vitalab, Byogene - dis- tributors of inputs for laboratories, marking Viveo's entry into the analytical segment (reagents) — and Flexicotton, a leader in the manufacture of hygiene products for its own brand. In addition, the company acquired 35.71% of the share capital of Far.Me, a startup from Minas Gerais, through which it expanded its activities with a service channel aimed at the end consumer. In 2021, the company's expansion plan was strengthened with the acquisition of Daviso and FW, specialized and leaders in the manufacture of wet wipes and towels dedicated to retail and wholesale segments, including its own brands. In order to enhance the operational and commercial synergy, expanding the range of services of- fered to the market, the following companies were ac- quired: Tecno4 and Pointmed, (distributors of medical products), and Laborsys, Apijā, and Macromed (distributors of inputs for laboratories) and surgical Mafra (a company that has physical stores and distribution centers for mar- keting hospital materials, special medicines, orthopedic products, dermo-cosmetics, among others). In addition to these acquisitions, the acquisition of Profarma Specialty (a distributor of medicines for hospitals and clinics), Med- care and Bemk (distributors of medical products) were announced 5. Thus, in 2021 this ecosystem was consolidated in Viveo, an institutional brand that brings together all the companies of the company, acting in an integrated way from produc- tion to delivery to the final consumer. The year was also marked by an important movement in the corporate area: in August, Viveo went public on B3, moving to trading common shares in order to raise funds to boost invest- ments the company was listed on Novo Mercado, B3's largest corporate governance segment. - In 2021, the ecosystem was consolidated through the institutional brand Viveo, which brings together all the company's companies. 5 By the end of 2021, these three acquisitions were awaiting approval from the Administrative Council for Economic Defense (CADE). viveo 14 Sustainability Report 2021

View entire presentation